125 related articles for article (PubMed ID: 30107365)
1. Purple acid phosphatase inhibitors as leads for osteoporosis chemotherapeutics.
Hussein WM; Feder D; Schenk G; Guddat LW; McGeary RP
Eur J Med Chem; 2018 Sep; 157():462-479. PubMed ID: 30107365
[TBL] [Abstract][Full Text] [Related]
2. Identification of purple acid phosphatase inhibitors by fragment-based screening: promising new leads for osteoporosis therapeutics.
Feder D; Hussein WM; Clayton DJ; Kan MW; Schenk G; McGeary RP; Guddat LW
Chem Biol Drug Des; 2012 Nov; 80(5):665-74. PubMed ID: 22943065
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, evaluation and structural investigations of potent purple acid phosphatase inhibitors as drug leads for osteoporosis.
Feder D; Kan MW; Hussein WM; Guddat LW; Schenk G; McGeary RP
Eur J Med Chem; 2019 Nov; 182():111611. PubMed ID: 31445230
[TBL] [Abstract][Full Text] [Related]
4. Synthesis, modelling and kinetic assays of potent inhibitors of purple acid phosphatase.
Mohd-Pahmi SH; Hussein WM; Schenk G; McGeary RP
Bioorg Med Chem Lett; 2011 May; 21(10):3092-4. PubMed ID: 21459576
[TBL] [Abstract][Full Text] [Related]
5. Diethylalkylsulfonamido(4-methoxyphenyl)methyl)phosphonate/phosphonic acid derivatives act as acid phosphatase inhibitors: synthesis accompanied by experimental and molecular modeling assessments.
Alimoradi N; Ashrafi-Kooshk MR; Shahlaei M; Maghsoudi S; Adibi H; McGeary RP; Khodarahmi R
J Enzyme Inhib Med Chem; 2017 Dec; 32(1):20-28. PubMed ID: 27766897
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of purple acid phosphatase with alpha-alkoxynaphthylmethylphosphonic acids.
McGeary RP; Vella P; Mak JY; Guddat LW; Schenk G
Bioorg Med Chem Lett; 2009 Jan; 19(1):163-6. PubMed ID: 19010677
[TBL] [Abstract][Full Text] [Related]
7. Optimization of an α-aminonaphthylmethylphosphonic acid inhibitor of purple acid phosphatase using rational structure-based design approaches.
Feder D; Mohd-Pahmi SH; Adibi H; Guddat LW; Schenk G; McGeary RP; Hussein WM
Eur J Med Chem; 2023 Jun; 254():115383. PubMed ID: 37087894
[TBL] [Abstract][Full Text] [Related]
8. Penicillin inhibitors of purple acid phosphatase.
Faridoon ; Hussein WM; Ul Islam N; Guddat LW; Schenk G; McGeary RP
Bioorg Med Chem Lett; 2012 Apr; 22(7):2555-9. PubMed ID: 22366658
[TBL] [Abstract][Full Text] [Related]
9. Phosphate forms an unusual tripodal complex with the Fe-Mn center of sweet potato purple acid phosphatase.
Schenk G; Gahan LR; Carrington LE; Mitic N; Valizadeh M; Hamilton SE; de Jersey J; Guddat LW
Proc Natl Acad Sci U S A; 2005 Jan; 102(2):273-8. PubMed ID: 15625111
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of Fe(III)-Zn(II) purple acid phosphatase based on crystal structures.
Klabunde T; Sträter N; Fröhlich R; Witzel H; Krebs B
J Mol Biol; 1996 Jun; 259(4):737-48. PubMed ID: 8683579
[TBL] [Abstract][Full Text] [Related]
11. Phosphotyrosyl peptides and analogues as substrates and inhibitors of purple acid phosphatases.
Valizadeh M; Schenk G; Nash K; Oddie GW; Guddat LW; Hume DA; de Jersey J; Burke TR; Hamilton S
Arch Biochem Biophys; 2004 Apr; 424(2):154-62. PubMed ID: 15047187
[TBL] [Abstract][Full Text] [Related]
12. Rational Design of Potent Inhibitors of a Metallohydrolase Using a Fragment-Based Approach.
Feder D; Mohd-Pahmi SH; Hussein WM; Guddat LW; McGeary RP; Schenk G
ChemMedChem; 2021 Nov; 16(21):3342-3359. PubMed ID: 34331400
[TBL] [Abstract][Full Text] [Related]
13. The applications of binuclear metallohydrolases in medicine: recent advances in the design and development of novel drug leads for purple acid phosphatases, metallo-β-lactamases and arginases.
McGeary RP; Schenk G; Guddat LW
Eur J Med Chem; 2014 Apr; 76():132-44. PubMed ID: 24583353
[TBL] [Abstract][Full Text] [Related]
14. Binuclear metal centers in plant purple acid phosphatases: Fe-Mn in sweet potato and Fe-Zn in soybean.
Schenk G; Ge Y; Carrington LE; Wynne CJ; Searle IR; Carroll BJ; Hamilton S; de Jersey J
Arch Biochem Biophys; 1999 Oct; 370(2):183-9. PubMed ID: 10510276
[TBL] [Abstract][Full Text] [Related]
15. Crystal structures of a purple acid phosphatase, representing different steps of this enzyme's catalytic cycle.
Schenk G; Elliott TW; Leung E; Carrington LE; Mitić N; Gahan LR; Guddat LW
BMC Struct Biol; 2008 Jan; 8():6. PubMed ID: 18234116
[TBL] [Abstract][Full Text] [Related]
16. Comparative studies of rat recombinant purple acid phosphatase and bone tartrate-resistant acid phosphatase.
Ek-Rylander B; Barkhem T; Ljusberg J; Ohman L; Andersson KK; Andersson G
Biochem J; 1997 Jan; 321 ( Pt 2)(Pt 2):305-11. PubMed ID: 9020859
[TBL] [Abstract][Full Text] [Related]
17. Electronic structure and spectro-structural correlations of Fe(III)Zn(II) biomimetics for purple acid phosphatases: relevance to DNA cleavage and cytotoxic activity.
Peralta RA; Bortoluzzi AJ; de Souza B; Jovito R; Xavier FR; Couto RA; Casellato A; Nome F; Dick A; Gahan LR; Schenk G; Hanson GR; de Paula FC; Pereira-Maia EC; de P Machado S; Severino PC; Pich C; Bortolotto T; Terenzi H; Castellano EE; Neves A; Riley MJ
Inorg Chem; 2010 Dec; 49(24):11421-38. PubMed ID: 21080710
[TBL] [Abstract][Full Text] [Related]
18. The glycosylphosphatidylinositol-anchored phosphatase from Spirodela oligorrhiza is a purple acid phosphatase.
Nakazato H; Okamoto T; Nishikoori M; Washio K; Morita N; Haraguchi K; Thompson GA; Okuyama H
Plant Physiol; 1998 Nov; 118(3):1015-20. PubMed ID: 9808746
[TBL] [Abstract][Full Text] [Related]
19. Fluoride inhibition of bovine spleen purple acid phosphatase: characterization of a ternary enzyme-phosphate-fluoride complex as a model for the active enzyme-substrate-hydroxide complex.
Pinkse MW; Merkx M; Averill BA
Biochemistry; 1999 Aug; 38(31):9926-36. PubMed ID: 10433699
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and evaluation of novel purple acid phosphatase inhibitors.
Hussein WM; Feder D; Schenk G; Guddat LW; McGeary RP
Medchemcomm; 2019 Jan; 10(1):61-71. PubMed ID: 30774855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
